Thyrocare Technologies Preet Kaur as Chief resigns
Thyrocare Technologies (THYROCARE) said Preet Kaur as Chief has resigned. The company is valued at about ₹7,887 crore.
What happened
In a filing with the NSE on 6 November 2026 at 04:31 PM, Thyrocare Technologies (THYROCARE) said that Preet Kaur as Chief has resigned.
From the filing: "Thyrocare Technologies Limited has informed the Exchange regarding Resignation of Dr."
Company snapshot
Thyrocare Technologies is a small-cap company in the Healthcare sector, with a market value of about ₹7,887 crore.
The stock last traded at ₹495.5, against a 52-week range of ₹342.6–₹662 (25.1% below the high).
Before this filing the shares had moved −8.6% over the month and −17.4% over three months. Average daily turnover over the last 20 sessions was about ₹34.23 crore.
Promoters held 51.02% at the end of Q2 FY27, down 9.90% points from the previous quarter. Foreign institutions owned 9.37% and domestic institutions 25.92%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 217 | 48 | 9.05 |
| Q3 FY26 | 196 | 29 | 1.82 |
| Q4 FY26 | 224 | 47.1 | 2.99 |
| Q1 FY27 | 240 | 52.2 | 3.23 |
| Q2 FY27 | 271 | 15.9 | 0.96 |
What history shows
This is not the company's first management change disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 4.3% on average the next trading day and was up 0.6% on average after five days (2 filings with price data).
Across 123 similar disclosures by other Healthcare companies, shares moved +1.1% on average the next day and +1.8% over five days; 50% of them rose the next day.
Market-wide, 4,295 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 45% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 23 Jul 2026 | Re-Appointment Of Internal Auditor Of The Company | +7.1% | +6.2% |
| 30 Jun 2026 | Change in Auditors of the company. | +1.4% | −5.0% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Thyrocare Revenue Up 25% in Q2; Profit Hit by ₹45 Cr Impairment
- Thyrocare Technologies Ltd (BOM:539871) (Q2 2027) Earnings Call Highlights: Record Franchisee ...
- Thyrocare Technologies Limited
- Thyrocare Q2 results: Profit falls as impairment charge weighs on earnings
- Thyrocare enters pregnancy testing segment, appoints Yami Gautam as brand ambassador
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.